罗非昔布所致颅内高压

Intracranial hypertension induced by rofecoxib.

作者信息

Jacob Saiju, Rajabally Yusuf A

机构信息

University Hospitals of Leicester, Neurology, Leicester, UK.

出版信息

Headache. 2005 Jan;45(1):75-6. doi: 10.1111/j.1526-4610.2005.05013.x.

DOI:10.1111/j.1526-4610.2005.05013.x

PMID:15663617

Abstract

Several secondary causes are implicated in the etiology of idiopathic intracranial hypertension. Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We report a case of intracranial hypertension in a 69-year-old man 3 weeks after the commencement of rofecoxib therapy with reversal of clinical findings on drug withdrawal.

摘要

特发性颅内高压的病因涉及多种继发因素。罗非昔布是一种选择性环氧化酶（COX）-2抑制剂，现在越来越多地用于替代非选择性非甾体抗炎药（NSAIDs）。我们报告一例69岁男性在开始罗非昔布治疗3周后出现颅内高压的病例，停药后临床症状逆转。